Key result
Aliskiren/amlodipine combination therapy provided a more effective systolic blood pressure reduction than aliskiren monotherapy (WMD -10.42) or amlodipine monotherapy (WMD -4.85) without increasing adverse events.
Why the study?
Does combination therapy with aliskiren and amlodipine improve blood pressure reduction compared to monotherapy in adults with essential hypertension?
Population
6,074 adults with essential hypertension pooled from 7 randomized controlled trials.
Comparison
Combination therapy of aliskiren and amlodipine. vs Monotherapy with either aliskiren or amlodipine.
Design
Meta-analysis
Follow-up
6 to 8 weeks
Authors
Loading...
Supports aliskiren/amlodipine combination in essential hypertension; extends Level-1 evidence beyond individual trials.
Meta-Analysis (n=6,074)
Does combination therapy with aliskiren and amlodipine improve blood pressure reduction compared to monotherapy in adults with essential hypertension?
Effect estimate: WMD -10.42 (95% CI -13.03 to -7.82)
p-value: p=<0.00001
Combination therapy with aliskiren and amlodipine provides superior blood pressure reduction compared to either drug alone without increasing overall adverse events, and may reduce amlodipine-induced peripheral edema.
Liu et al. (2013) conducted a meta-analysis in Essential Hypertension (n=6,074). Aliskiren and amlodipine combination therapy vs. Aliskiren or amlodipine monotherapy was evaluated on Systolic blood pressure reduction (combination vs aliskiren monotherapy) (WMD -10.42, 95% CI -13.03 to -7.82, p=<0.00001). Aliskiren/amlodipine combination therapy provided a more effective systolic blood pressure reduction than aliskiren monotherapy (WMD -10.42) or amlodipine monotherapy (WMD -4.85) without increasing adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: